Kagocel, tablets 12 mg 30 pcs

Pharmacotherapeutic group: Antiviral agent.

ATX CODE: [J05AX]

Pharmacological properties

Pharmacodinamics

The main mechanism of action of Kagocel® is the ability to induce production of interferons. Kagocel® causes formation of so-called late interferons in the human body, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel® causes production of interferons in almost all cell populations participating in antiviral response: T- and B- lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When oral administration of one dose of Kagocel® interferon titer in blood serum reaches its maximum values after 48 hours. Interferon response to Kagocel® administration is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine when taking Kagocel® orally does not coincide with the dynamics of circulating interferon titers. In serum interferon production reaches high values only 48 hours after Kagocel® administration, while in the intestine maximum interferon production is observed after 4 hours.

Cagocel® when administered in therapeutic doses is non-toxic and does not accumulate in the body. The drug has no mutagenic and teratogenic properties, is not carcinogenic and has no embryotoxic effect.

The drug is most effective when used with Kagocel® not later than the 4th day after the onset of an acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the infectious agent.

Pharmacokinetics

24 hours after administration Kagocel® accumulates in the body mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel® in brain is due to the high molecular weight of the drug, making it difficult to penetrate through the blood-brain barrier. In blood plasma the drug is mainly in bound form.

When daily repeated administration of Kagocel® the volume of distribution varies over a wide range in all organs studied. Accumulation of the drug in the spleen and lymph nodes is particularly pronounced. When administered orally, about 20% of the administered drug dose enters the general bloodstream. Absorbed drug circulates in blood mainly in macromolecule-bound form: with lipids – 47%, with proteins – 37%. The unbound part of the drug is about 16%.

Indications

Kagocel® is used in adults and children over 3 years old as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARI), as well as a therapeutic agent for herpes in adults.

Active ingredient

Kagocel

Composition

Active ingredient: Cagocel® 12 mg.

Excipients: potato starch – 10 mg, calcium stearate – 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Collidon 30), crosspovidone (Collidon CL). – to obtain a tablet with a mass of 100 mg.

How to take, the dosage

Over the body, regardless of meals.

For the treatment of flu and acute respiratory infections in adults, the first two days – 2 tablets 3 times a day, in the next two days – one tablet 3 times a day. A total of 18 tablets for the course, the duration of the course is 4 days.

The prophylaxis of flu and acute respiratory viral infections in adults is carried out in 7-day cycles: two days with 2 tablets once a day, a 5-day break, then the cycle is repeated. The duration of the prophylactic course is from one week to several months.

For the treatment of herpes in adults 2 tablets 3 times a day for 5 days are prescribed. The course of treatment consists of 30 tablets for 5 days.

For the treatment of flu and acute respiratory viral infections in children of 3 to 6 years old it is prescribed for the first two days – 1 tablet 2 times a day, for the next two days – 1 tablet once a day. A total of 6 tablets for the course, the duration of the course is 4 days.

For the treatment of flu and acute respiratory infections in children over 6 years of age, it is prescribed for the first two days – one tablet three times a day, on the next two days – one tablet two times a day. The course of treatment consists of 10 tablets for a total of 4 days.

Preventive treatment of influenza and SARS in children at the age of 3 years is carried out in 7-day cycles: 2 days – 1 tablet once a day, 5 days break, and then the cycle is repeated. The duration of the prophylactic course is from one week to several months.

Interaction

Kagocel® combines well with other antiviral drugs, immunomodulators and antibiotics (additive effect).

Special Instructions

To achieve a therapeutic effect, start taking Kagocel® no later than the fourth day from the beginning of the disease.

Contraindications

– Pregnancy and lactation;
– Age up to 3 years;
– Hypersensitivity to the drug components;
– Lactose deficiency, lactose intolerance, glucose-galactose malabsorption.

Side effects

Allergic reactions may develop.

If any of the side effects listed in the instructions are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

In case of an accidental overdose, it is recommended to give plenty of fluids and induce vomiting.

Pregnancy use

Because of the lack of necessary clinical data, Kagocel® is not recommended for use during pregnancy and lactation.